A5068720824- Colorectal Cancer Surgical Treatments
- Esophageal and GI Pathology
- Colorectal and Anal Carcinomas
- Gastric Cancer Management and Outcomes
- Esophageal Cancer Research and Treatment
- Appendicitis Diagnosis and Management
- Intraperitoneal and Appendiceal Malignancies
- Colorectal Cancer Screening and Detection
- Pancreatic and Hepatic Oncology Research
- Ovarian cancer diagnosis and treatment
- Hepatitis B Virus Studies
- Liver Disease Diagnosis and Treatment
- Gastroesophageal reflux and treatments
- Economic and Financial Impacts of Cancer
- Enhanced Recovery After Surgery
- Hepatitis C virus research
- Neutropenia and Cancer Infections
- Nail Diseases and Treatments
- Cancer Mechanisms and Therapy
- Palliative Care and End-of-Life Issues
- Immunotherapy and Immune Responses
- Neuroendocrine Tumor Research Advances
- Cancer Immunotherapy and Biomarkers
- Wound Healing and Treatments
- RNA modifications and cancer
Tel Aviv University
2021-2024
Memorial Sloan Kettering Cancer Center
2022-2024
Rabin Medical Center
2021-2024
Icahn School of Medicine at Mount Sinai
2016-2022
Carmel Medical Center
2015
Ben-Gurion University of the Negev
2006
Gastric cancer (GC) is the third leading cause of deaths and fourth most prevalent malignancy worldwide. The high incidence mortality rates gastric result from multiple factors such as ineffective screening, diagnosis, limited treatment options. In our study, we sought to systematically identify predictive molecular networks key regulators elucidate complex interacting signaling pathways in GC. We performed an integrative network analysis transcriptomic data Cancer Genome Atlas (TCGA) cohort...
In the United States, hepatocellular carcinoma (HCC) is more common among communities with low socioeconomic status (SES), and these groups tend to be diagnosed later-stage cancers. Sorafenib primary treatment for advanced HCC, however its substantial cost raises concern access treatment.The newly developed Case-Background method was used estimate odds ratios impacts of various sociodemographic factors on sorafenib in clinically eligible patients. Socioeconomic defined as a factor median...
Keloid scar is pathological tissue that appears after skin injury, and more aggressive than hypertrophic scars. scars are characterized by increased proliferation of fibroblast-like cells (FLCs) the accumulation extracellular matrix, mainly collagen. Fibulin-5, a glycoprotein secreted many cell types, component matrix. We investigated effect fibulin-5 on adhesion FLCs derived from keloid role integrin beta-1 in these activities.Fibroblast-like were isolated six cultured plates coated with or...
The American College of Surgeons (ACS) recently published quality assurance (QA) indicators for pancreatic cancer care. Implementing in a newly formed health system may lead to better patient selection and standardized care.Select ACS internal were implemented wide 2014. We compared compliance with these measures before after their implementation at the main hospital two new affiliate institutions.A total 506 patients included. At pre-QA period, 11 (12.6%) 87 discussed our institutional...
ABSTRACT Background Total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC) has shown promise in achieving pathologic complete response (pCR) and enabling organ preservation through watch‐and‐wait (WW) strategies. However, implementation of WW protocols diverse patient populations safety‐net hospitals faces unique challenges. The objective this study is to evaluate TNT outcomes identify barriers a predominantly Hispanic hospital South Texas. Methods A retrospective review...
Abstract INTRODUCTION Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, yet their efficacy remains limited. Therefore, there is a clear need for new anti-tumor agents. HVEM (Herpes Virus Entry Mediator) plays regulatory role in immunity, making it promising therapeutic target. EXPERIMENTAL DESIGN We developed Anti-4CB1, fully human HVEM-BTLA and HVEM-CD160 blocking mAb tested its activity various in-vitro, ex-vivo in-vivo models, alone or combination with Anti-PD1....
BACKGROUND: Anal adenocarcinoma bears a treatment strategy unique to other anal cancers. OBJECTIVE: To describe oncologic outcomes of total neoadjuvant therapy followed by watch and wait for adenocarcinoma. DESIGN: Retrospective analysis. SETTING: This study was conducted at comprehensive cancer center. PATIENTS: Patients with treated between 2004 2019 were selected. INTERVENTIONS: Fifty-four patients received divided into two groups according their strategy: versus single-neoadjuvant...
Favorable pathologic response(FPR) is a significant predictor for improved survival following Neoadjuvant therapy(NAT) in esophageal and gastroesophageal cancer(GEJ). Preoperative prediction of FPR could modify treatment plans. No reliable method predicting exists. We sought to identify preoperative factors FPR.Retrospective analysis patients with GEJ cancer who underwent esophagectomy (NAT). Univariate multivariate was used FPR. A comparison Tumor Regression Grade(TRG) assess response on...